Form 4: Astera Labs GC Sells Shares Under 10b5-1 Plan

Astera Labs' General Counsel and Secretary, Philip Mazzara, sold 9,000 shares of common stock on March 2, 2026, through a pre-arranged 10b5-1 trading plan.

Summary

• Philip Mazzara, General Counsel and Secretary of Astera Labs, Inc. (ALAB), reported the sale of 9,000 shares of common stock.
• The transactions occurred on March 2, 2026, at weighted average prices ranging from $113.847 to $120.98 per share.
• These sales were executed automatically pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Mazzara on May 29, 2025.
• Following these transactions, Mr. Mazzara beneficially owns 128,084 shares of Astera Labs common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event because the sales were pre-scheduled under a 10b5-1 plan, which typically signals a planned diversification or liquidity event rather than a reaction to new, negative company-specific information.

Negatives

• The reduction in insider ownership, even if planned, can sometimes be perceived negatively by some market participants.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider selling, particularly by high-ranking officers, is a common occurrence for compensation and diversification purposes. The use of a Rule 10b5-1 plan indicates a pre-scheduled transaction, reducing the implication of immediate negative sentiment compared to unplanned sales.

Stakeholder Impact

• Shareholders may observe a slight decrease in insider ownership, but the pre-arranged nature of the sales under a 10b5-1 plan mitigates concerns about management's confidence in the company's future.

Key Dates

Recommendation

The insider selling by a corporate officer, while a reduction in direct ownership, was conducted under a pre-established 10b5-1 trading plan. This suggests a planned financial diversification or liquidity event rather than a reaction to new material non-public information. Therefore, it does not fundamentally alter the investment thesis for Astera Labs, warranting a 'hold' recommendation based solely on this filing.

Keywords

Astera Labs, ALAB, Insider Selling, Form 4, Philip Mazzara, 10b5-1 Plan, Stock Sale, Corporate Officer, Equity Transaction